{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:58:04Z","timestamp":1793642284158,"version":"4.5.1"},"reference-count":106,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T00:00:00Z","timestamp":1650758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaacap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jaac.2022.03.033","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T20:45:13Z","timestamp":1650660313000},"page":"151-168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6992-0767","authenticated-orcid":false,"given":"Gonzalo","family":"Salazar de Pablo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5247-6508","authenticated-orcid":false,"given":"Carolina","family":"Pastor Jord\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2224-6314","authenticated-orcid":false,"given":"Julio","family":"Vaquerizo-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0541-4846","authenticated-orcid":false,"given":"Carmen","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2391-8247","authenticated-orcid":false,"given":"Anna","family":"Cabras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3382-4754","authenticated-orcid":false,"given":"Celso","family":"Arango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2319-3525","authenticated-orcid":false,"given":"Patricia","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6349-1076","authenticated-orcid":false,"given":"Jeremy","family":"Veenstra-VanderWeele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5450-0823","authenticated-orcid":false,"given":"Emily","family":"Simonoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3582-6788","authenticated-orcid":false,"given":"Paolo","family":"Fusar-Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4830-5893","authenticated-orcid":false,"given":"Paramala","family":"Santosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5877-8075","authenticated-orcid":false,"given":"Samuele","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7977-3601","authenticated-orcid":false,"given":"Mara","family":"Parellada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaac.2022.03.033_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"issue":"7","key":"10.1016\/j.jaac.2022.03.033_bib2","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s10803-013-2022-5","article-title":"Emotion dysregulation and the core features of autism spectrum disorder","volume":"44","author":"Samson","year":"2014","journal-title":"J\u00a0Autism Dev Disord"},{"key":"10.1016\/j.jaac.2022.03.033_bib3","series-title":"Irritability","author":"Vorvick","year":"2009"},{"issue":"Suppl 2","key":"10.1016\/j.jaac.2022.03.033_bib4","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1542\/peds.2015-2851K","article-title":"Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis","volume":"137","author":"Fung","year":"2016","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.jaac.2022.03.033_bib5","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1176\/appi.ajp.2014.13101301","article-title":"Disruptive mood dysregulation disorder: a new diagnostic approach to chronic irritability in youth","volume":"171","author":"Roy","year":"2014","journal-title":"Am J Psychiatry. Sep"},{"issue":"2","key":"10.1016\/j.jaac.2022.03.033_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1089\/cap.2015.0074","article-title":"Disruptive mood dysregulation disorder symptoms and association with oppositional defiant and other disorders in a general population child sample","volume":"26","author":"Mayes","year":"2016","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"8","key":"10.1016\/j.jaac.2022.03.033_bib7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jaac.2015.06.001","article-title":"The Research Domain Criteria (RDoC) Project and studies of risk and resilience in maltreated children","volume":"54","author":"Kaufman","year":"2015","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.jaac.2022.03.033_bib8","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1590\/1516-4446-2013-S107","article-title":"Irritability in children and adolescents: past concepts, current debates, and future opportunities","volume":"35","author":"Krieger","year":"2013","journal-title":"Braz J Psychiatry"},{"issue":"7","key":"10.1016\/j.jaac.2022.03.033_bib10","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/aur.1968","article-title":"Emotion regulation in autism spectrum disorder: where we are and where we need to go","volume":"11","author":"Cai","year":"2018","journal-title":"Autism Res"},{"issue":"8","key":"10.1016\/j.jaac.2022.03.033_bib11","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/aur.2295","article-title":"Gender differences in emotion dysregulation in an autism inpatient psychiatric sample","volume":"13","author":"Wieckowski","year":"2020","journal-title":"Autism Res"},{"issue":"1","key":"10.1016\/j.jaac.2022.03.033_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/aur.2450","article-title":"Emotion dysregulation is substantially elevated in autism compared to the general population: impact on psychiatric services","volume":"14","author":"Conner","year":"2021","journal-title":"Autism Res"},{"issue":"7","key":"10.1016\/j.jaac.2022.03.033_bib13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jaac.2013.05.006","article-title":"The role of emotion regulation in autism spectrum disorder","volume":"52","author":"Mazefsky","year":"2013","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.jaac.2022.03.033_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eurpsy.2013.02.005","article-title":"The neurobiology of autism spectrum disorders","volume":"29","author":"Parellada","year":"2014","journal-title":"Eur Psychiatry"},{"issue":"5","key":"10.1016\/j.jaac.2022.03.033_bib15","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/jcpp.13003","article-title":"The dysregulation profile in preschoolers with and without a family history of autism spectrum disorder","volume":"60","author":"Miller","year":"2019","journal-title":"J\u00a0Child Psychol Psychiatry"},{"issue":"6","key":"10.1016\/j.jaac.2022.03.033_bib16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/aur.1947","article-title":"The Emotion Dysregulation Inventory: psychometric properties and item response theory calibration in an autism spectrum disorder sample","volume":"11","author":"Mazefsky","year":"2018","journal-title":"Autism Res"},{"issue":"3","key":"10.1016\/j.jaac.2022.03.033_bib17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/cap.2018.0115","article-title":"Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis","volume":"29","author":"Fallah","year":"2019","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.jaac.2022.03.033_bib18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11920-010-0172-0","article-title":"Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial","volume":"13","author":"Benton","year":"2011","journal-title":"Curr Psychiatry Rep"},{"issue":"4","key":"10.1016\/j.jaac.2022.03.033_bib19","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/npp.2009.202","article-title":"Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders","volume":"35","author":"Hollander","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jaac.2022.03.033_bib20","doi-asserted-by":"crossref","first-page":"110326","DOI":"10.1016\/j.pnpbp.2021.110326","article-title":"The pediatric psychopharmacology of autism spectrum disorder: a systematic review\u2500part I: the past and the present","volume":"110","author":"Persico","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"9","key":"10.1016\/j.jaac.2022.03.033_bib21","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1007\/s10803-018-3562-5","article-title":"A\u00a0randomized placebo-controlled cross-over pilot study of riluzole for drug-refractory irritability in autism spectrum disorder","volume":"48","author":"Wink","year":"2018","journal-title":"J\u00a0Autism\u00a0Dev Disord"},{"key":"10.1016\/j.jaac.2022.03.033_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.psychres.2019.04.013","article-title":"Prevalence and predictors of psychotropic medication use in adolescents and adults with autism spectrum disorder in Italy: a cross-sectional study","volume":"276","author":"Fusar-Poli","year":"2019","journal-title":"Psychiatry Res"},{"issue":"6","key":"10.1016\/j.jaac.2022.03.033_bib23","first-page":"389","article-title":"Pharmacological therapies for autism spectrum disorder: a review","volume":"40","author":"LeClerc","year":"2015","journal-title":"P\u00a0T"},{"issue":"2","key":"10.1016\/j.jaac.2022.03.033_bib24","first-page":"110","article-title":"Clonidine as a treatment of behavioural disturbances in autism spectrum disorder: a systematic literature review","volume":"29","author":"Banas","year":"2020","journal-title":"J\u00a0Can Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2022.03.033_bib25","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jaac.2022.03.033_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003583","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"18","author":"Page","year":"2021","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.jaac.2022.03.033_bib27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.beth.2019.09.006","article-title":"The internal structure of the Aberrant Behavior Checklist Irritability Subscale: implications for studies of irritability in treatment-seeking youth with autism spectrum disorders","volume":"51","author":"Stoddard","year":"2020","journal-title":"Behav Ther"},{"issue":"4","key":"10.1016\/j.jaac.2022.03.033_bib28","doi-asserted-by":"crossref","first-page":"e19070","DOI":"10.1371\/journal.pone.0019070","article-title":"How to obtain NNT from Cohen's d: comparison of two methods","volume":"6","author":"Furukawa","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jaac.2022.03.033_bib29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/HRP.0000000000000294","article-title":"Universal and selective interventions to prevent poor mental health outcomes in young people: systematic review and meta-analysis","volume":"29","author":"Salazar de Pablo","year":"2021","journal-title":"Harv Rev Psychiatry"},{"issue":"5","key":"10.1016\/j.jaac.2022.03.033_bib30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/cap.2009.0120","article-title":"Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder","volume":"20","author":"Aman","year":"2010","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"3","key":"10.1016\/j.jaac.2022.03.033_bib31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"7109","key":"10.1016\/j.jaac.2022.03.033_bib32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clin Research ed)"},{"key":"10.1016\/j.jaac.2022.03.033_bib33","series-title":"Practical Meta-analysis","author":"Lipsey","year":"2000"},{"key":"10.1016\/j.jaac.2022.03.033_bib34","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"key":"10.1016\/j.jaac.2022.03.033_bib35","series-title":"Comprehensive Meta-Analysis Version 3 [computer program]","year":"2013"},{"key":"10.1016\/j.jaac.2022.03.033_bib36","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jaac.2022.03.033_bib37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4088\/JCP.13m08500","article-title":"A\u00a0randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder","volume":"75","author":"Findling","year":"2014","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.jaac.2022.03.033_bib38","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s10578-016-0704-x","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: a randomized, double-blind, placebo-controlled study","volume":"48","author":"Ichikawa","year":"2017","journal-title":"Child Psychiatry Hum Dev"},{"issue":"6","key":"10.1016\/j.jaac.2022.03.033_bib39","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.jaac.2022.03.033_bib40","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10803-012-1723-5","article-title":"Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study","volume":"43","author":"Kent","year":"2013","journal-title":"J\u00a0Autism Dev Disord"},{"issue":"5","key":"10.1016\/j.jaac.2022.03.033_bib41","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems","volume":"347","author":"McCracken","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.jaac.2022.03.033_bib42","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.55.7.633","article-title":"A\u00a0double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders","volume":"55","author":"McDougle","year":"1998","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"10.1016\/j.jaac.2022.03.033_bib43","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/08830738060210060801","article-title":"Risperidone in children with autism: randomized, placebo-controlled, double-blind study","volume":"21","author":"Nagaraj","year":"2006","journal-title":"J\u00a0Child Neurol"},{"issue":"5","key":"10.1016\/j.jaac.2022.03.033_bib44","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/jir.12584","article-title":"Is risperidone effective in reducing challenging behaviours in individuals with intellectual disabilities after 1 year or longer use? A placebo-controlled, randomised, double-blind discontinuation study","volume":"63","author":"Ramerman","year":"2019","journal-title":"J\u00a0Intellect Disabil Res"},{"issue":"5","key":"10.1016\/j.jaac.2022.03.033_bib45","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.jaac.2022.03.033_bib46","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s10803-015-2628-x","article-title":"Lurasidone for the treatment of irritability associated with autistic disorder","volume":"46","author":"Loebel","year":"2016","journal-title":"J\u00a0Autism Dev Disord"},{"issue":"4","key":"10.1016\/j.jaac.2022.03.033_bib47","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/00004714-200108000-00012","article-title":"Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study","volume":"21","author":"Remington","year":"2001","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.jaac.2022.03.033_bib48","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1001\/archgenpsychiatry.2009.30","article-title":"Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism","volume":"66","author":"King","year":"2009","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"10.1016\/j.jaac.2022.03.033_bib49","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hup.491","article-title":"Tianeptine: a novel strategy of psychopharmacological treatment of children with autistic disorder","volume":"18","author":"Niederhofer","year":"2003","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.jaac.2022.03.033_bib50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2217\/14750708.1.1.87","article-title":"Venlafaxine has modest effects in autistic children","volume":"1","author":"Niederhofer","year":"2004","journal-title":"Therapy"},{"issue":"2","key":"10.1016\/j.jaac.2022.03.033_bib51","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1010799115457","article-title":"Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Belsito","year":"2001","journal-title":"J\u00a0Autism Dev Disord"},{"issue":"4","key":"10.1016\/j.jaac.2022.03.033_bib52","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/cap.2005.15.682","article-title":"A\u00a0double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders","volume":"15","author":"Hellings","year":"2005","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.jaac.2022.03.033_bib53","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.yic.0000224787.13782.0f","article-title":"Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study","volume":"21","author":"Wasserman","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"issue":"10","key":"10.1016\/j.jaac.2022.03.033_bib54","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1097\/01.chi.0000231976.28719.2a","article-title":"Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial","volume":"45","author":"Arnold","year":"2006","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"10.1016\/j.jaac.2022.03.033_bib55","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1023\/A:1005548619694","article-title":"Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder","volume":"30","author":"Handen","year":"2000","journal-title":"J\u00a0Autism Dev Disord"},{"issue":"5","key":"10.1016\/j.jaac.2022.03.033_bib56","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00004714-199210000-00005","article-title":"Clonidine treatment of hyperactive and impulsive children with autistic disorder","volume":"12","author":"Jaselskis","year":"1992","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.jaac.2022.03.033_bib57","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF02179289","article-title":"Use of methylphenidate in the treatment of children with autistic disorder","volume":"25","author":"Quintana","year":"1995","journal-title":"J\u00a0Autism Dev Disord"},{"issue":"1","key":"10.1016\/j.jaac.2022.03.033_bib58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/1362361307070989","article-title":"A\u00a0placebo double-blind pilot study of dextromethorphan for problematic behaviors in children with autism","volume":"11","author":"Woodard","year":"2007","journal-title":"Autism"},{"issue":"12","key":"10.1016\/j.jaac.2022.03.033_bib59","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/0006-3223(95)00297-9","article-title":"The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study","volume":"39","author":"Willemsen-Swinkels","year":"1996","journal-title":"Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.jaac.2022.03.033_bib60","first-page":"1532","article-title":"A\u00a0randomized, placebo-controlled, blinded, crossover, pilot study of the effects of dextromethorphan\/quinidine for the treatment of neurobehavioral symptoms in adults with autism","volume":"50","author":"Chez","year":"2020","journal-title":"J\u00a0Autism\u00a0Dev\u00a0Disorders"},{"issue":"6","key":"10.1016\/j.jaac.2022.03.033_bib61","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/00004583-200106000-00010","article-title":"Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder","volume":"40","author":"King","year":"2001","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2022.03.033_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/S0924-977X(16)31879-X","article-title":"The safety and efficacy of memantine hydrochloride versus placebo for children under 3 years old with autism spectrum disorders","volume":"26","author":"Martsenkovsky","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"issue":"7","key":"10.1016\/j.jaac.2022.03.033_bib63","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jaac.2020.07.888","article-title":"Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): a single center, double-blinded, participant-randomized, placebo-controlled, phase-2 superiority trial","volume":"60","author":"Sprengers","year":"2020","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"10.1016\/j.jaac.2022.03.033_bib64","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/npp.2016.232","article-title":"A\u00a0single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder","volume":"42","author":"Umbricht","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.jaac.2022.03.033_bib65","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1023\/A:1015493412224","article-title":"Double-blind placebo-controlled trial of secretin: Effects on aberrant behavior in children with autism","volume":"32","author":"Carey","year":"2002","journal-title":"J\u00a0Autism Dev Disord"},{"issue":"3","key":"10.1016\/j.jaac.2022.03.033_bib66","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/WNF.0000000000000213","article-title":"A\u00a0placebo-controlled crossover trial of gastrin-releasing peptide in childhood autism","volume":"40","author":"Marchezan","year":"2017","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jaac.2022.03.033_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2016.00002","article-title":"Oxytocin for male subjects with autism spectrum disorder and comorbid intellectual disabilities: a randomized pilot study","volume":"7","author":"Munesue","year":"2016","journal-title":"Front Psychiatry"},{"issue":"11","key":"10.1016\/j.jaac.2022.03.033_bib68","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1097\/00004583-200111000-00009","article-title":"Multisite, double-blind, placebo-controlled trial of porcine secretin in autism","volume":"40","author":"Owley","year":"2001","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"10.1016\/j.jaac.2022.03.033_bib69","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/00004583-200211000-00012","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of porcine versus synthetic secretin for reducing symptoms of autism","volume":"41","author":"Unis","year":"2002","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.jaac.2022.03.033_bib70","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaac.2014.01.018","article-title":"Internet-based, randomized, controlled trial of omega-3 fatty acids for hyperactivity in autism","volume":"53","author":"Bent","year":"2014","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"4","key":"10.1016\/j.jaac.2022.03.033_bib71","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.biopsych.2006.05.007","article-title":"Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study","volume":"61","author":"Amminger","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jaac.2022.03.033_bib72","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsbmb.2018.10.017","article-title":"A\u00a0randomised controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with autism spectrum disorder","volume":"187","author":"Mazahery","year":"2019","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"issue":"2","key":"10.1016\/j.jaac.2022.03.033_bib73","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/JCP.0b013e3182485791","article-title":"Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: a double-blind, placebo-controlled, randomized trial","volume":"32","author":"Yui","year":"2012","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"10.1016\/j.jaac.2022.03.033_bib74","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.biopsych.2012.01.014","article-title":"A\u00a0randomized controlled pilot trial of oral N-acetylcysteine in children with autism","volume":"71","author":"Hardan","year":"2012","journal-title":"Biol Psychiatry"},{"issue":"8","key":"10.1016\/j.jaac.2022.03.033_bib75","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1007\/s10803-018-3536-7","article-title":"An exploratory trial of transdermal nicotine for aggression and irritability in adults with autism spectrum disorder","volume":"48","author":"Lewis","year":"2018","journal-title":"J\u00a0Autism Dev Disord"},{"issue":"7","key":"10.1016\/j.jaac.2022.03.033_bib76","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/npp.2016.237","article-title":"Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial","volume":"42","author":"Veenstra-VanderWeele","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.jaac.2022.03.033_bib77","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1089\/cap.2011.0056","article-title":"Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders","volume":"22","author":"Arnold","year":"2012","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"11","key":"10.1016\/j.jaac.2022.03.033_bib78","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/CHI.0b013e3181b76658","article-title":"A\u00a0placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder","volume":"48","author":"Marcus","year":"2009","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.jaac.2022.03.033_bib79","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/phar.2271","article-title":"Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial","volume":"39","author":"DeVane","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.jaac.2022.03.033_bib80","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10578-013-0390-x","article-title":"A\u00a0head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial","volume":"45","author":"Ghanizadeh","year":"2014","journal-title":"Child Psychiatry Hum Dev"},{"key":"10.1016\/j.jaac.2022.03.033_bib81","series-title":"The Maudsley Prescribing Guidelines","author":"Taylor","year":"2018"},{"key":"10.1016\/j.jaac.2022.03.033_bib82","author":"Stahl"},{"issue":"5","key":"10.1016\/j.jaac.2022.03.033_bib83","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40272-020-00408-0","article-title":"Recent advances in the pharmacological management of behavioral disturbances associated with autism spectrum disorder in children and adolescents","volume":"22","author":"Lamy","year":"2020","journal-title":"Paediatr Drugs"},{"issue":"11","key":"10.1016\/j.jaac.2022.03.033_bib84","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1007\/s10803-015-2446-1","article-title":"Brief report of preliminary outcomes of an emotion regulation intervention for children with autism spectrum disorder","volume":"45","author":"Thomson","year":"2015","journal-title":"J\u00a0Autism Dev Disord"},{"key":"10.1016\/j.jaac.2022.03.033_bib85","doi-asserted-by":"crossref","unstructured":"Parent V, Birtwell KB, Lambright N, DuBard M. Combining CBT and behavior-analytic approaches to target severe emotion dysregulation in verbal youth with ASD and ID. J Ment Health Res Intellect Disabil. 2016. 2016;9(1-2):60-82. https:\/\/doi.org\/10.1080\/19315864.2016.1166301","DOI":"10.1080\/19315864.2016.1166301"},{"issue":"3","key":"10.1016\/j.jaac.2022.03.033_bib86","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1521\/bumc.2019.83.3.205","article-title":"Emotion regulation: a treatment target for autism spectrum disorder","volume":"83","author":"Reyes","year":"2019","journal-title":"Bull Menninger Clin"},{"issue":"1","key":"10.1016\/j.jaac.2022.03.033_bib87","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.chc.2013.07.002","article-title":"Emotion regulation: concepts & practice in autism spectrum disorder","volume":"23","author":"Mazefsky","year":"2014","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"issue":"5","key":"10.1016\/j.jaac.2022.03.033_bib88","doi-asserted-by":"crossref","first-page":"432","DOI":"10.30773\/pi.2019.0229","article-title":"Efficacy of interventions based on applied behavior analysis for autism spectrum disorder: a meta-analysis","volume":"17","author":"Yu","year":"2020","journal-title":"Psychiatry Invest"},{"issue":"12","key":"10.1016\/j.jaac.2022.03.033_bib89","article-title":"Early intervention with parents of children with autism spectrum disorders: a review of programs","volume":"7","author":"Rojas-Torres","year":"2020","journal-title":"Children (Basel)"},{"key":"10.1016\/j.jaac.2022.03.033_bib90","article-title":"Implementing precision psychiatry: a systematic review of individualized prediction models for clinical practice","author":"Salazar de Pablo","year":"2020","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jaac.2022.03.033_bib91","article-title":"Practitioner review: pharmacological treatment of attention-deficit\/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis","author":"Rodrigues","year":"2020","journal-title":"J\u00a0Child Psychol Psychiatry"},{"issue":"2","key":"10.1016\/j.jaac.2022.03.033_bib92","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jaac.2019.12.009","article-title":"Stepped treatment for attention-deficit\/hyperactivity disorder and aggressive behavior: a randomized, controlled trial of adjunctive risperidone, divalproex sodium, or placebo after stimulant medication optimization","volume":"60","author":"Blader","year":"2021","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2022.03.033_bib93","doi-asserted-by":"crossref","DOI":"10.1177\/2045125319862968","article-title":"Treatment of psychoses in patients with epilepsy: an update","volume":"9","author":"Agrawal","year":"2019","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.jaac.2022.03.033_bib94","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.phrs.2016.03.022","article-title":"The pharmacological management of psychiatric comorbidities in patients with epilepsy","volume":"107","author":"Mula","year":"2016","journal-title":"Pharmacol Res"},{"issue":"3","key":"10.1016\/j.jaac.2022.03.033_bib95","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.nurt.2010.06.001","article-title":"Medical comorbidities in autism: challenges to diagnosis and treatment","volume":"7","author":"Bauman","year":"2010","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.jaac.2022.03.033_bib96","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/WNF.0000000000000096","article-title":"Mood stabilizers in children and adolescents with autism spectrum disorders","volume":"38","author":"Canitano","year":"2015","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"10.1016\/j.jaac.2022.03.033_bib97","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2042098618756261","article-title":"Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine","volume":"9","author":"De Berardis","year":"2018","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.jaac.2022.03.033_bib98","first-page":"CD011412","article-title":"Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data","volume":"12","author":"Nevitt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.jaac.2022.03.033_bib99","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/epi.13981","article-title":"Comparative efficacy of antiepileptic drugs in children and adolescents: a network meta-analysis","volume":"59","author":"Rosati","year":"2018","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.jaac.2022.03.033_bib100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/cap.2009.0022","article-title":"Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability","volume":"20","author":"Arnold","year":"2010","journal-title":"J Child Adolesc Psychopharmacology"},{"issue":"9","key":"10.1016\/j.jaac.2022.03.033_bib101","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s00213-019-05235-x","article-title":"Effects of haloperidol on the delta-9-tetrahydrocannabinol response in humans: a responder analysis","volume":"236","author":"Gupta","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"issue":"14","key":"10.1016\/j.jaac.2022.03.033_bib102","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2165\/00023210-200418140-00006","article-title":"Pharmacotherapy of pervasive developmental disorders in children and adolescents","volume":"18","author":"Masi","year":"2004","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.jaac.2022.03.033_bib103","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41380-021-01134-w","article-title":"Placebo and nocebo responses in randomised, controlled trials of medications for ADHD: a systematic review and meta-analysis","volume":"27","author":"Faraone","year":"2021","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10.1016\/j.jaac.2022.03.033_bib104","doi-asserted-by":"crossref","DOI":"10.1186\/s13229-020-00372-z","article-title":"Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis","volume":"11","author":"Siafis","year":"2020","journal-title":"Mol Autism"},{"issue":"10","key":"10.1016\/j.jaac.2022.03.033_bib105","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaac.2018.05.024","article-title":"What\u2019s in a name? Moving to neuroscience-based nomenclature in pediatric psychopharmacology","volume":"57","author":"Sultan","year":"2018","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"10.1016\/j.jaac.2022.03.033_bib106","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/pcn.12615","article-title":"Neuroscience-based nomenclature: what is it, why is it needed, and what comes next?","volume":"72","author":"Uchida","year":"2018","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.jaac.2022.03.033_bib107","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.4172\/2161-1459.1000e114","article-title":"Aberrant Behavior Checklist: current identity and future developments","volume":"2","author":"Aman","year":"2012","journal-title":"Clin Exp Pharmacol"}],"container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856722001988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856722001988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:34:44Z","timestamp":1760193284000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856722001988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":106,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0890856722001988"],"URL":"https:\/\/doi.org\/10.1016\/j.jaac.2022.03.033","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Child & Adolescent Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaac.2022.03.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92022 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}